SCHEMBL1863296

SCHEMBL1863296

O=C(O)NCc1ncccc1CNC(=O)c1ccc(Cl)nc1NCCc1cccc(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
KDM4E B2RXH2 3/20 0.47
GAA P10253 1/20 0.41
LMNA P02545 3/20 0.40
HTT P42858 2/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
RPS6KB1 P23443 1/20 0.39
CSNK2A2 P19784 2/20 0.38
CSNK2A1 P68400 2/20 0.38
GLA P06280 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ADORA2A P29274 2/20 0.38
ADORA1 P30542 2/20 0.38
PIK3CD O00329 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12629063 0.89 MAPT (0.42) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL1855062 0.86 MAPT (0.42) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL4117268 0.85 ROCK2 (0.42) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL1863294 0.85 MEN1 (0.46) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL14195485 0.84 MEN1 (0.46) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL4966576 0.84 MEN1 (0.42) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL4112138 0.83 ADORA2A (0.43) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL1855064 0.83 MEN1 (0.42) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL1630794 0.82 GBA1 (0.48) MAPTMEN1KMT2AL3MBTL1KDM4E
Hydrochloric Acid SCHEMBL1881988 0.81 GBA1 (0.48) MAPTMEN1KMT2AL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7939534-B2 e.g. (2-{[2-(3-fluorophenyl)ethyl]amino}-6-piperidyl(3-pyridyl))-N-(3-pyridylmethyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, chronic obstructive pulmonary disease, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction CYTOKINETICS, INC. (US) 2011-05-10 US disclosed
US-20080139575-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2008-06-12 US disclosed
WO-2008016643-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INCORPORATED (US) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139575-A1 Certain chemical entities, compositions, and methods MYLK, MYH2, MYH10 MAPT 540/4885MEN1 510/4885KMT2A 2544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.